Claritas HealthTech’s CystoSmart™: Revolutionary AI Diagnostic Tool for Bladder Cancer Detection Set to Transform Medical Diagnostics, Singapore

Date:

Claritas HealthTech’s CystoSmart™: Revolutionary AI Diagnostic Tool for Bladder Cancer Detection Set to Transform Medical Diagnostics

London and New York, November 12, 2023 (GLOBE NEWSWIRE) – Claritas HealthTech announces a groundbreaking development in medical diagnostics with its subsidiary, Intelligent Scopes Corp (ISC), leading the worldwide delivery and deployment of CystoSmart™. This revolutionary AI diagnostic tool aims to transform the detection of bladder cancer through cutting-edge technology and image enhancement.

Bladder cancer is a prevalent form of cancer, ranking as the 10th most common cancer globally and the sixth most common in men. However, diagnostics using cystoscopes for bladder examination pose numerous challenges and require significant time and resources. CystoSmart™, developed through a research collaboration agreement with Khoo Teck Puat Hospital (KTPH) Singapore and with support from Singapore’s National Healthcare Group (NHG)’s Centre for Medical Technologies and Innovations (CMTi), presents an innovative solution to address these challenges.

CystoSmart™ utilizes image enhancement and artificial intelligence to achieve real-time precision detection of conditions in endoscopic and cystoscopic images, ensuring accurate identification of bladder cancer. The system is currently under review for clearance by the FDA, marking a significant step toward revolutionizing bladder cancer diagnostics.

Dr. Laszlo Neumann, Chief Technology Officer of Claritas, expresses excitement about the collaboration, stating, We are excited to be working with Singapore’s clinical team in developing CystoSmart™. Our joint objective has been to develop a precision AI tool that can be used as an aid by clinicians to significantly improve patient care.

Dr. Siying Yeow, clinical principal investigator for CystoSmart™ and a consultant urologist at KTPH, echoes this sentiment, emphasizing the tool’s potential to enhance the accuracy of bladder cancer detection. Our aim has been to develop an AI diagnostic tool that enhances the accuracy of detection of bladder cancers, says Dr. Yeow. CystoSmart™ will be beneficial in enabling appropriate treatment for newly diagnosed cancers, the accurate recognition of tumor recurrences, and complete tumor resection during surgery.

See also  Spotify CEO's Neko Health Secures €60 Million Funding for Medical Startup

Claritas HealthTech, a leader in image enhancement and AI diagnostic solutions, focuses on research and development in medical image processing and AI-assisted interpretation and diagnostics. Compliant with HIPAA, PDPA, and GDPR requirements, Claritas aims to transform the diagnostics industry through powerful and effective software products created using their advanced technology.

Intelligent Scopes Corp, a subsidiary of Claritas, specializes in providing state-of-the-art image processing and enhancement software medical devices and AI diagnostic tools for urology and gastroenterology. Their strategic focus on research and development of image processing, image enhancement, AI diagnostic tools, and robotic guidance systems aims to improve detection rates, reduce unnecessary biopsies, and enhance patient outcomes.

Khoo Teck Puat Hospital (KTPH), a public hospital, is part of Singapore’s National Healthcare Group (NHG). With a focus on serving the northern sector of Singapore, KTPH provides general and acute care to more than 550,000 individuals. The collaboration with KTPH and the support from Singapore’s NHG’s Centre for Medical Technologies and Innovations (CMTi) have been instrumental in the development of CystoSmart™.

The deployment of CystoSmart™ is set to revolutionize bladder cancer diagnostics and improve patient outcomes worldwide. Through its AI-assisted detection capabilities and accurate recognition of bladder cancers, CystoSmart™ aims to enable timely treatment and enhance surgical procedures, ensuring an improved standard of care for individuals affected by this form of cancer.

For media inquiries or further information, please contact:

Claritas HealthTech: www.claritashealthtech.com

Intelligent Scopes Corp: www.intelligentscopes.com

Khoo Teck Puat Hospital (KTPH): https://www.ktph.com.sg/

Frequently Asked Questions (FAQs) Related to the Above News

What is CystoSmart™?

CystoSmart™ is a revolutionary AI diagnostic tool developed by Claritas HealthTech's subsidiary, Intelligent Scopes Corp (ISC), in collaboration with Khoo Teck Puat Hospital (KTPH) Singapore and support from Singapore's National Healthcare Group (NHG)'s Centre for Medical Technologies and Innovations (CMTi). It utilizes image enhancement and artificial intelligence to provide real-time precision detection of conditions in endoscopic and cystoscopic images, specifically focusing on accurate identification of bladder cancer.

Why is bladder cancer detection important?

Bladder cancer is a prevalent form of cancer and ranks as the 10th most common cancer globally, with it being the sixth most common in men. Early detection of bladder cancer is crucial for timely treatment and improving patient outcomes. However, the current diagnostics using cystoscopes for bladder examination pose challenges and require significant time and resources. CystoSmart™ aims to address these challenges and enhance the accuracy of bladder cancer detection.

How does CystoSmart™ work?

CystoSmart™ utilizes advanced image enhancement and artificial intelligence technology to analyze endoscopic and cystoscopic images in real-time. It applies AI algorithms to enhance the images and identify potential signs of bladder cancer with precision and accuracy. By providing clinicians with a powerful AI tool, CystoSmart™ aims to improve the diagnostic process and assist in making informed treatment decisions.

Has CystoSmart™ received regulatory clearance?

Currently, CystoSmart™ is under review for clearance by the FDA. This regulatory process is an important step towards the widespread implementation and adoption of this innovative AI diagnostic tool for bladder cancer detection.

How can CystoSmart™ benefit patients and healthcare providers?

CystoSmart™ aims to significantly improve patient care by enhancing the accuracy of bladder cancer detection. It can assist clinicians in providing appropriate treatment for newly diagnosed cancers, accurately recognizing tumor recurrences, and aiding in complete tumor resection during surgery. Furthermore, by streamlining the diagnostic process and reducing unnecessary biopsies, CystoSmart™ can help improve efficiency and patient outcomes.

Is CystoSmart™ compliant with data protection regulations?

Yes, Claritas HealthTech, the parent company of Intelligent Scopes Corp, ensures that CystoSmart™ complies with data protection regulations such as HIPAA, PDPA, and GDPR. Patient privacy and data security are prioritized to maintain ethical standards and protect sensitive medical information.

How can I learn more about Claritas HealthTech, ISC, and KTPH?

To learn more about Claritas HealthTech, ISC, and KTPH, you can visit their respective websites: - Claritas HealthTech: www.claritashealthtech.com - Intelligent Scopes Corp: www.intelligentscopes.com - Khoo Teck Puat Hospital (KTPH): https://www.ktph.com.sg/

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

Microsoft Unveils Copilot+ PCs: Mind-Blowing AI Speed and Smarts Await!

Experience mind-blowing AI speed and smarts with Microsoft's Copilot+ PCs. Pre-order now and revolutionize your computing experience!

Global AI Summit in Seoul: Leaders Discuss Safe and Sustainable Regulations

Join global leaders at the AI Seoul Summit 2024 to discuss safe and sustainable AI regulations. Learn more about the future of AI development!

PwC Study: AI Skills Boost Wages by 25% Globally

Discover how AI skills can boost wages by 25% globally and revolutionize productivity in the global economy. Gain insights from the PwC study.

Scarlett Johansson Accuses OpenAI of Cloning Her Voice

Scarlett Johansson accuses OpenAI of cloning her voice without consent for their ChatGPT project. Debate on ethics of voice cloning sparked.